Induction of quinone reductase by tamoxifen or DPN protects against mammary tumorigenesis.

We have previously shown that estrogen receptor β (ERβ)-mediated up-regulation of quinone reductase (QR) is involved in the protection against estrogen-induced mammary tumorigenesis. Our present study provides evidence that the ERβ agonist, 2,3-bis-(4-hydroxy-phenyl)-propionitrile (DPN), and the selective estrogen receptor modulator tamoxifen (Tam), inhibit estrogen-induced DNA damage and mammary tumorigenesis in the aromatase transgenic (Arom) mouse model. We also show that either DPN or Tam treatment increases QR levels and results in a decrease in ductal hyperplasia, proliferation, oxidative DNA damage (ODD), and an increase in apoptosis. To corroborate the role of QR, we provide additional evidence in triple transgenic MMTV/QR/Arom mice, wherein the QR expression is induced in the mammary glands via doxycycline, causing a decrease in ductal hyperplasia and ODD. Overall, we provide evidence that up-regulation of QR through induction by Tam or DPN can inhibit estrogen-induced ODD and mammary cell tumorigenesis, representing a novel mechanism of prevention against breast cancer. Thus, our data have important clinical implications in the management of breast cancer; our findings bring forth potentially new therapeutic strategies involving ERβ agonists.

Citation

Nirmala Krishnamurthy, Yanduan Hu, Sandra Siedlak, Yong Qiu Doughman, Michiko Watanabe, Monica M Montano. Induction of quinone reductase by tamoxifen or DPN protects against mammary tumorigenesis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2012 Oct;26(10):3993-4002

Mesh Tags

Substances

PMID: 22700872

search → result